Lorinda Burgess
CIK: 0001843912
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jul 15, 2026ANGO
ANGIODYNAMICS INC
Award(A)Direct11.9K shares- - May 8, 2026SCL
STEPAN CO
Award(A)Direct2.6K shares at avg. $52.61$135K - Jul 16, 2025ANGO
ANGIODYNAMICS INC
Award(A)Direct17.7K shares- - May 12, 2025SCL
STEPAN CO
Award(A)DirectStock Awards
2.5K shares at avg. $54.26- - Apr 1, 2025SCL
STEPAN CO
Award(A)DirectStock Awards
10 shares at avg. $55.40-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 15, 2026 |  ANGO ANGIODYNAMICS INC | Award(A) | 11,887 | - | $0 | Direct |
| May 8, 2026 |  SCL STEPAN CO | Award(A) | 2,566 | $52.61 | $134,997 | Direct |
| Jul 16, 2025 | ANGO ANGIODYNAMICS INC | Award(A) | 17,675 | - | - | Direct |
| May 12, 2025 | SCL STEPAN CO | Award(A) Stock Awards | 2,500 | $54.26 | - | Direct |
| Apr 1, 2025 | SCL STEPAN CO | Award(A) Stock Awards | 10 | $55.40 | - | Direct |
1-5 of 5 transactions
About Burgess Lorinda
Burgess Lorinda (SEC CIK 0001843912) files insider reports with the SEC as Director of ANGIODYNAMICS INC (ANGO) and Director of STEPAN CO (SCL).
Signal8 holds 5 ownership filings by Burgess Lorinda, all Form 4s, filed between Apr 3, 2025 and Jul 22, 2026. Those filings report 5 transactions, from Apr 1, 2025 to Jul 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Burgess Lorinda's filings is in LATHAM, NY.
Recent filings by Burgess Lorinda
- Jul 15, 2026: Grant or award of ANGO shares (Form 4, code A).
- May 8, 2026: Grant or award of SCL shares (Form 4, code A).
- Jul 16, 2025: Grant or award of ANGO shares (Form 4, code A).
- May 12, 2025: Grant or award of SCL derivative securities (Form 4, code A).
- Apr 1, 2025: Grant or award of SCL derivative securities (Form 4, code A).
Other insiders filing for ANGIODYNAMICS INC (ANGO)
- Trowbridge Stephen A, EVP and CFO
- Piccinini Laura, SVP International
- Nighan Warren JR, SVP Quality and Regulatory
- Clemmer James C, President and CEO
- Campbell Chad Thomas, SVP/GM, Vascular Access
- REED JAN STERN, Director